January 03, 2024 BY Elizabeth Anderson
Rise in US FDA approvals may signal an upsurge in biotech investments
Some prominent therapeutics were featured in the 2023-approval batch. These included Zepbound, an obesity treatment developed by Eli Lilly and Company (LLY), and Leqembi, an Alzheimer's drug from Eisai (ESAYI) and Biogen Inc. (BIIB). On top of the 55 novel drug green lights, the FDA also put its stamp of approval on five gene therapies.…
Read more